EGFR Resistance in NSCLC: Q2 2026 Intelligence Brief | Lumaris

Downloadable PDF Brief<br>Keep the full EGFR resistance brief on hand.<br>Download the professionally formatted PDF version of this Q2 2026 analysis — including the full findings, competitive landscape, references, and Lumaris methodology note.<br>Download the full brief — $19Need a custom report for your pipeline? — $499

Section I<br>Executive Summary<br>Osimertinib (AstraZeneca's TAGRISSO) remains the first-line standard of care for patients with EGFR-mutant (Ex19del or L858R) advanced NSCLC. Yet a majority of patients will develop acquired resistance within two to three years, and the mechanistic landscape of that resistance has matured considerably since 2024. Three signals now dominate the clinical literature and are reshaping both first- and second-line development strategy.<br>First, MET amplification has solidified as the single most frequent on-target bypass mechanism , occurring in approximately 13% of patients progressing on first-line osimertinib — a figure significantly higher than historical estimates. The MARIPOSA trial (amivantamab + lazertinib vs. osimertinib) demonstrated that upfront dual EGFR/MET blockade reduces the incidence of MET-driven acquired resistance from 13.1% to 3.4% at progression (P=0.002), validating the mechanism's tractability and raising the strategic question of whether to use combination therapy upfront or sequence MET-targeted therapy after osimertinib failure.<br>Second, the C797S tertiary mutation — a cysteine-to-serine substitution at codon 797 — emerges in 6–12% of patients on first-line osimertinib and effectively abrogates covalent binding of all approved third-generation EGFR TKIs. A wave of fourth-generation agents targeting this variant is now entering Phase 1/2 trials, creating a new competitive battleground.<br>Third, amivantamab-based combinations have emerged as the leading post-osimertinib platform , with CHRYSALIS-2, MARIPOSA-2, and updated PAPILLON data establishing amivantamab as active regardless of the dominant resistance mechanism. This represents a significant strategic repositioning — from a one-size-fits-all osimertinib re-challenge strategy to a biomarker-informed sequencing algorithm.

Section II<br>Key Findings<br>Synthesized from 2,400+ peer-reviewed publications and clinical trial reports, 2023–Q2 2026.

01MET Amplification Is the Dominant On-Target Bypass Mechanism — and It Is Preventable<br>High Signal

MET amplification drives approximately 13% of acquired resistance events in patients receiving first-line osimertinib — higher than estimates derived from earlier biopsy-limited studies. A landmark analysis from the MARIPOSA trial, presented at WCLC 2025 and published in the Journal of Thoracic Oncology, quantified this precisely: 13.1% of patients at progression on osimertinib monotherapy harbored MET amplification, compared to only 3.4% in the amivantamab + lazertinib arm (P=0.002).<br>This translational dataset is significant for two reasons. First, it confirms MET bypass as the largest single druggable mechanism of acquired EGFR TKI resistance, larger than C797S, HER2 amplification, or transformation to SCLC. Second, it validates the mechanistic rationale for upfront EGFR/MET dual blockade — the combination literally suppresses the emergence of the dominant escape route.<br>Strategic implication: For programs developing MET inhibitors or MET-directed combination strategies, positioning post-osimertinib remains viable (since >10% of failures are MET-driven), but the MARIPOSA data will place competitive pressure on that space as amivantamab + lazertinib is adopted upfront.<br>Key references: Passaro et al., WCLC 2025 (IASLC abstract); Kim et al., J Thorac Oncol 2025; MARIPOSA trial (NCT04487080).

02C797S Tertiary Mutation Opens a New Fourth-Generation EGFR TKI Race<br>High Signal

The C797S gatekeeper mutation — arising at the cysteine residue that osimertinib and other third-generation EGFR TKIs require for covalent binding — has emerged in 6–12% of patients treated with first-line osimertinib, a higher frequency than observed in the post-second-generation TKI setting. C797S abrogates activity of all approved EGFR TKIs when it co-occurs with the sensitizing T790M mutation (as is typical with tertiary resistance), creating a patient population with few effective options.<br>Multiple programs are now targeting this mutation with allosteric (non-covalent) or mutant-selective fourth-generation approaches:<br>BI 1810631 (Boehringer Ingelheim) — a non-covalent, wild-type-sparing fourth-generation EGFR TKI in Phase 1 (NCT04820023); early data published in 2024 indicate tolerability and preliminary anti-tumor activity in C797S-harboring tumors.<br>BLU-701 (Blueprint Medicines / Roche) — an allosteric EGFR inhibitor designed to be active against C797S; Phase 1/2 SYMPHONY trial ongoing (NCT05276492).<br>EAI045 + cetuximab (academic programs) — allosteric EGFR combination rationale being explored in translational models; clinical entry...